EUCTR2015-005699-21-IT进行中（未招募）1 期
An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and RefractoryMultiple Myeloma - NA
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 512
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Measurable Disease
- •-Have received= 2 lines of prior therapy which must have included at
- •least 2 consecutive cycles of an immune modulatory drug (IMID) and a
- •proteasome inhibitor alone or in combination.
- •-Documented progression from most recent therapy
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 1
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 154
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 358
排除标准
- •-Solitary bone or extramedullary plasmacytoma disease only
- •-Active plasma cell leukemia
- •-monoclonal gammopathy of undetermined significance (MGUS),
- •smoldering multiple myeloma (SMM), amyloidosis, Waldenstrom's
- •macroglobulinemia, or POEMS syndrome (plasma cell dyscrasia with poly
- •neuropathy, organomegaly,
- •endocrinopathy, monoclonal protein, and skin changes)
研究者
相似试验
进行中（未招募）
1 期
Phase 3 Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple Myelomarelapsed and refractory Multiple MyelomaMedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000054086EUCTR2015-005699-21-PLBristol-Myers Squibb International Corporation512
进行中（未招募）
1 期
Phase 3 Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple MyelomaEUCTR2015-005699-21-ESBristol-Myers Squibb International Corporation170
进行中（未招募）
1 期
An investigational immuno-therapy study of Nivolumab, Pomalidomide andDexamethasone combinations in patients with Multiple MyelomaEUCTR2015-005699-21-CZBristol-Myers Squibb International Corporation417
进行中（未招募）
1 期
Phase 3 Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple Myelomarelapsed and refractory Multiple MyelomaMedDRA version: 19.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2015-005699-21-NOBristol-Myers Squibb International Corporation512
进行中（未招募）
1 期
Phase 3 Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple Myelomarelapsed and refractory Multiple MyelomaMedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2015-005699-21-GRBristol-Myers Squibb International Corporation512